^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
Published date:
08/25/2020
Excerpt:
BRAF V600E-mutated colorectal (WiDr, RKO, Colo 201, and LS411N) and melanoma (G361 and A375) cell lines were treated with each drug covering a 10,000-fold concentration range....Similarly, PLX8394 showed greater potency than vemurafenib in 5 out of 6 cell lines (P < 0.0001 A375, LS411N, WiDr, RKO, and Colo 201,...
DOI:
https://doi.org/10.18632/oncotarget.27681
